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Like other glands, the prostate is surrounded by connective tissue, or stroma, containing several cell types that help maintain the gland's normal growth and function. 6 In the event of injury or infection, some stromal cells secrete molecules such as cytokines and growth factors to reduce inflammation, guard against infection, and foster healing. 7, 8 Tumor cells can provoke a similar reaction, but instead of restoring normalcy, the response may actually help the tumor cells thrive.
8,9,10
Adipose-derived mesenchymal/stromal stem cells (ASCs) are particularly noteworthy in this context because they are drawn to tumors and concentrate in their vicinity. 9 Given the concentration of ASCs in a tumor's microenvironment, disruption of their normal function could affect tumor progression. Based on the evidence of a link between arsenic and prostate cancer, 4 the authors hypothesized that arsenic could cause such disruption.
To test their hypothesis, the researchers conducted in vitro experiments with ASCs and a human prostate cancer cell line (PC3 cells). ASCs were cultured in media with 1, 10, or 75 ppb arsenic, and the media were analyzed to identify cytokines secreted by the cells. This analysis showed both up-regulation of tumor-promoting cytokines and downregulation of tumor-suppressing cytokines, compared with unexposed cells. Proteomic analysis of the ASCs identified proteins whose expression was altered in the presence of arsenic, and further analysis uncovered a statistically significant relationship between increased expression of the protein heme oxygenase-1 and decreased expression of the protein thrombospondin-1. Both proteins are associated with the transforming growth factor-β signaling pathway, 8 which plays a significant regulatory role in the progression of prostate cancer.
10 A separate experiment confirmed that arsenic down-regulated this pathway in the ASCs. In other experiments, ASCs were cultured in media with 0 or 75 ppb arsenic, then washed and exchanged with arsenic-free media. This allowed for the collection of factors secreted by the ASCs. These conditioned media, minus the ASCs, were then used to culture PC3 cells. PC3 cell viability increased in media from arsenic-exposed but not nonexposed ASCs. The data collectively implied that arsenic causes ASCs to alter their response to tumor cells in a manner that enhances the growth of tumors.
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The researchers stress, however, that the study does not indicate that the stroma itself causes cancer. "It's instead creating an environment that is more suitable for cancer to progress," says lead author Joseph Shearer, a graduate student in pharmacology and toxicology at the University of Texas Medical Branch at Galveston.
Coauthor Marxa Figueiredo, an assistant professor of basic medical sciences at Purdue University, adds that cancer could be started by any number of factors, including genetic mutations or exposures to various other environmental contaminants. "In real life, we're not impacted just by arsenic-we're impacted by multiple mixtures of contaminants throughout our lives," she says.
Although conducted in prostate cell culture, the study highlights a potentially important role of the stroma in other cancers. "We don't have a complete understanding of how similar or different these stromal cells and microenvironments are between the different cancers," says David Rowley, a professor of molecular and cellular biology at Baylor College of Medicine who was not involved in the study. "One could well imagine that exposure to something like arsenic would affect stroma in much the same way in many tissues. It wouldn't surprise me if similar effects were seen in other tumor cell types."
In fact, the impact of a dysregulated stroma could persist even in the absence of a tumor, according to Shearer. "When a tumor is excised, the reactive stroma could potentially still be relevant," he says. "You have to think about not just treating the tumor, but also whether the environment is still aberrantly regulated." With that in mind, the new findings highlight a possible route for improving cancer treatment someday.
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